Warp Drive Bio constructs a new cancer R&D tech platform

Cambridge, MA-based Warp Drive Bio is launching a new cancer drug platform which the biotech claims will open up new, previously undruggable targets to developers. The work is built on their insights into a "novel composite surface" that can be used to target cancer with new therapies. And their first target--RAS--encompasses both the challenges as well as the potential of what they're trying to do. Release

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.